Funding
MYELOMA
Open Access funding enabled and organized by Projekt DEAL. The German Speaking Myeloma Multicenter Group (GMMG) initiated and designed the HD6 and HD7 trial. The investigational medicinal products isatuximab and lenalidomide were provided by Sanofi and Bristol Myers Squibb/Celgene, respectively. Sanofi funded the GMMG HD7 trial via an externally sponsored collaboration. The GMMG HD6 trial was supported by grants from Bristol Myers Squibb, Chugai and Celgene.